Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Abbisko Therapeutics Co. Ltd. currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. Both of these actions are located within 1 distinct art unit, suggesting a narrow technical focus for the company's current filings. The prosecution involves 2 distinct examiners, meaning each action is being reviewed by a different person despite being in the same art unit. This structure requires the company to manage 2 unique sets of examiner expectations within a single technical group.
Daniel John Burkett is the busiest examiner for the portfolio, overseeing 1 pending office action. The use of 2 distinct examiners for only 2 actions within a single art unit highlights a lack of examiner concentration. Practitioners can expect to manage different examiner preferences even when dealing with the same art unit. This structure suggests that while the technology is focused, the human element of prosecution is divided, requiring separate approaches for each of the 2 pending office actions. Success in this 1 distinct art unit will depend on the ability to tailor arguments to the specific tendencies of the 2 distinct examiners involved. The company must ensure its prosecution strategy is flexible enough to accommodate these different perspectives.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BURKETT, DANIEL JOHN | 1 | 62.6% | +33.2% |
| O DELL, DAVID K | 1 | 57.7% | +36.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18691683 | PYRAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | O DELL, DAVID K | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18844821 | HOLOSYMMETRIC BIPHENYL DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | BURKETT, DANIEL JOHN | — |
| 18691683 | PYRAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | O DELL, DAVID K | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18844821 | HOLOSYMMETRIC BIPHENYL DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | BURKETT, DANIEL JOHN | — | §112 | Non-Final OA | — | Pending | Sep 06, 2024 |
| 18691683 | PYRAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | O DELL, DAVID K | 1621 | §102§103 | Non-Final OA | — | Pending | Mar 13, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial